L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients.
L-threo-3,4-dihydroxyphenylserine (L-DOPS) was administered to six parkinsonian patients for the treatment of gait related akinesia which was refractile to L-DOPA treatment. One responded with marked improvement and one with only mild improvement. Although number of patients who respond markedly to this noradrenaline precursor, L-DOPS, is limited, L-DOPS was felt to be the most effective treatment modality for L-DOPA refractile gait related akinesia and L-DOPA related orthostatic hypotension.
Yoshida
M
M
Noguchi
S
S
Kuramoto
S
S
D000368:Aged; D001072:Apraxias / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D015103:Droxidopa / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005684:Gait / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D012694:Serine
D012694:Serine; D015103:Droxidopa